Bedell Frazier Investment Counselling LLC Buys 92 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Bedell Frazier Investment Counselling LLC grew its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 1.9% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 4,905 shares of the biopharmaceutical company’s stock after purchasing an additional 92 shares during the quarter. Bedell Frazier Investment Counselling LLC’s holdings in Regeneron Pharmaceuticals were worth $3,494,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. AIA Group Ltd raised its position in shares of Regeneron Pharmaceuticals by 27.8% in the 4th quarter. AIA Group Ltd now owns 13,600 shares of the biopharmaceutical company’s stock worth $9,688,000 after acquiring an additional 2,959 shares in the last quarter. Clearbridge Investments LLC grew its stake in Regeneron Pharmaceuticals by 0.7% during the fourth quarter. Clearbridge Investments LLC now owns 3,978 shares of the biopharmaceutical company’s stock worth $2,834,000 after purchasing an additional 26 shares during the period. RWA Wealth Partners LLC increased its holdings in Regeneron Pharmaceuticals by 4,518.0% in the fourth quarter. RWA Wealth Partners LLC now owns 18,426 shares of the biopharmaceutical company’s stock worth $13,125,000 after purchasing an additional 18,027 shares in the last quarter. Allianz SE bought a new stake in Regeneron Pharmaceuticals in the fourth quarter worth approximately $96,000. Finally, Allstate Corp bought a new position in shares of Regeneron Pharmaceuticals during the 4th quarter worth approximately $2,276,000. 83.31% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several analysts have recently weighed in on the stock. Sanford C. Bernstein lowered their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating for the company in a research note on Tuesday, January 7th. Robert W. Baird decreased their price target on shares of Regeneron Pharmaceuticals from $940.00 to $759.00 and set a “neutral” rating for the company in a research note on Wednesday, February 5th. Bank of America reissued an “underperform” rating and set a $565.00 price objective on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 10th. Leerink Partnrs raised Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Finally, TD Cowen dropped their price target on Regeneron Pharmaceuticals from $1,230.00 to $1,030.00 and set a “buy” rating on the stock in a research note on Tuesday, February 4th. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $973.13.

Regeneron Pharmaceuticals Trading Up 0.2 %

NASDAQ REGN opened at $637.36 on Monday. The business’s fifty day moving average is $683.88 and its 200-day moving average is $795.57. The company has a debt-to-equity ratio of 0.09, a current ratio of 4.73 and a quick ratio of 3.95. The stock has a market capitalization of $69.68 billion, a price-to-earnings ratio of 16.65, a PEG ratio of 2.34 and a beta of 0.27. Regeneron Pharmaceuticals, Inc. has a one year low of $629.02 and a one year high of $1,211.20.

Regeneron Pharmaceuticals (NASDAQ:REGN) last announced its quarterly earnings data on Tuesday, February 4th. The biopharmaceutical company reported $12.07 EPS for the quarter, topping the consensus estimate of $11.21 by $0.86. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business had revenue of $3.79 billion for the quarter, compared to analyst estimates of $3.76 billion. During the same quarter in the previous year, the firm posted $11.86 earnings per share. The company’s revenue for the quarter was up 10.3% on a year-over-year basis. Equities research analysts predict that Regeneron Pharmaceuticals, Inc. will post 35.92 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The company also recently disclosed a quarterly dividend, which was paid on Thursday, March 20th. Shareholders of record on Thursday, February 20th were issued a dividend of $0.88 per share. This represents a $3.52 annualized dividend and a yield of 0.55%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals’s dividend payout ratio (DPR) is 2.30%.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.